Recent News

• 06.06.2025 - Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
• 06.05.2025 - Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference
• 06.03.2025 - Addex Convenes Annual General Meeting 2025
• 05.12.2025 - Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
• 04.30.2025 - Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
• 04.25.2025 - Addex Reports Full Year 2024 Financial Results and Provides Corporate Update
• 04.24.2025 - Addex Therapeutics to Release Full-Year 2024 Financial Results and Host Conference Call on April 25, 2025
• 04.17.2025 - Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
• 01.08.2025 - Addex to Present at the 2025 Swiss Equities Baader Conference
• 11.22.2024 - Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Recent Filings

• 05.15.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 05.12.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.12.2025 - EX-99.1 EX-99.1
• 04.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.30.2025 - NT 20-F Notification of inability to timely file Form 20-F
• 04.30.2025 - EX-99.1 EX-99.1
• 04.25.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.17.2025 - EX-99.1 EX-99.1
• 04.17.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.22.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]